Australia's most trusted
source of pharma news
Monday, 22 December 2025
Posted 22 December 2025 AM
A good result for a string of big name drugs that did battle with the PBAC at the November meeting - though there were repeated calls for price cuts and not everyone made it over the finish line.
It was third time lucky for Novo Nordisk which scored a recommendation for its obesity drug Wegovy in patients with established cardiovascular disease with obesity, after failing in obesity in March 2022 and severe obesity in November 2023.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.